Curated News
By: NewsRamp Editorial Staff
November 13, 2024
Tonix Pharmaceuticals Develops TNX-801 Vaccine for Monkeypox and Smallpox
Discuss on Reddit
LinkedIn
Substack
GithubTLDR
- TNX-801 offers reduced virulence and protection against Clade Ia monkeypox, positioning it as a single-dose vaccine candidate for public health emergencies.
- Tonix Pharmaceuticals advances TNX-801 with FDA feedback, large-scale manufacturing collaborations, and planned clinical trials in Kenya for broad, long-lasting immunity.
- Tonix's TNX-801 vaccine could provide durable protection against monkeypox and smallpox outbreaks, contributing to global health security and disease prevention efforts.
- TNX-801, a new vaccine candidate, shows promising results in preclinical studies, offering potential solutions for future infectious disease challenges.
Impact - Why it Matters
This news highlights the innovative efforts of Tonix Pharmaceuticals in developing a vaccine with the potential to provide durable protection against monkeypox and smallpox outbreaks. The development of TNX-801 could have significant implications for public health and global disease prevention strategies.
Summary
Tonix Pharmaceuticals (NASDAQ: TNXP) has published new data demonstrating that TNX-801, a vaccine, shows reduced virulence compared to traditional vaccines and provides protection against monkeypox. The company is positioning TNX-801 as a single-dose vaccine candidate for durable protection against outbreaks.
Tonix is advancing TNX-801’s development with FDA feedback and collaborations for large-scale manufacturing. The company believes its vaccine could offer broad, long-lasting immunity against both monkeypox and smallpox.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Tonix Pharmaceuticals Develops TNX-801 Vaccine for Monkeypox and Smallpox
